WO2001007027A3 - Pyrimidine derivatives for the treatment of viral diseases - Google Patents

Pyrimidine derivatives for the treatment of viral diseases Download PDF

Info

Publication number
WO2001007027A3
WO2001007027A3 PCT/US2000/019650 US0019650W WO0107027A3 WO 2001007027 A3 WO2001007027 A3 WO 2001007027A3 US 0019650 W US0019650 W US 0019650W WO 0107027 A3 WO0107027 A3 WO 0107027A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
treatment
preferred
viral diseases
pyrimidine derivatives
Prior art date
Application number
PCT/US2000/019650
Other languages
French (fr)
Other versions
WO2001007027A2 (en
Inventor
Michael Hale
Francois Maltais
Christopher Baker
James Janetka
Young Choon Moon
Jeffrey Saunders
Original Assignee
Vertex Pharma
Michael Hale
Francois Maltais
Christopher Baker
James Janetka
Young Choon Moon
Jeffrey Saunders
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma, Michael Hale, Francois Maltais, Christopher Baker, James Janetka, Young Choon Moon, Jeffrey Saunders filed Critical Vertex Pharma
Priority to AU61110/00A priority Critical patent/AU6111000A/en
Publication of WO2001007027A2 publication Critical patent/WO2001007027A2/en
Publication of WO2001007027A3 publication Critical patent/WO2001007027A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a method useful for inhibiting viral helicases, and in particular, the hepatitis C virus NS3 helicase. The method employs compositions having formula (I) where R?1, R2, R3, R4¿, X and T are as described herein. Preferred compounds are those where R3 is an electron withdrawing group such as halo, CN or CO¿2R?1. More preferred are those compounds where R3 is an electron withdrawing group and R2 is OH. Most preferred are those compounds where R?2 and R3¿ are as just described and X is S. In particular, the compositions and methods of this invention are useful in treating diseases caused by hepatitis C virus, bovine viral diarrhea virus or vaccinia virus.
PCT/US2000/019650 1999-07-22 2000-07-19 Pyrimidine derivatives for the treatment of viral diseases WO2001007027A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU61110/00A AU6111000A (en) 1999-07-22 2000-07-19 Inhibitors of viral helcase

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14519399P 1999-07-22 1999-07-22
US60/145,193 1999-07-22
US15078399P 1999-08-26 1999-08-26
US60/150,783 1999-08-26

Publications (2)

Publication Number Publication Date
WO2001007027A2 WO2001007027A2 (en) 2001-02-01
WO2001007027A3 true WO2001007027A3 (en) 2001-08-09

Family

ID=26842750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/019650 WO2001007027A2 (en) 1999-07-22 2000-07-19 Pyrimidine derivatives for the treatment of viral diseases

Country Status (2)

Country Link
AU (1) AU6111000A (en)
WO (1) WO2001007027A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4186484B2 (en) 2002-03-12 2008-11-26 住友化学株式会社 Pyrimidine compounds and uses thereof
TWI312272B (en) 2003-05-12 2009-07-21 Sumitomo Chemical Co Pyrimidine compound and pests controlling composition containing the same
JPWO2005019225A1 (en) * 2003-08-21 2007-11-01 杏林製薬株式会社 Method for producing compound having NK1 receptor antagonistic activity and production intermediate thereof
EP2206715A1 (en) 2004-02-24 2010-07-14 Japan Tobacco, Inc. Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
WO2007047146A2 (en) * 2005-10-11 2007-04-26 Intermune, Inc. Inhibitors of viral replication
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
AU2007323335A1 (en) * 2006-11-23 2008-05-29 Novartis Ag Pyrimidines and their use as CXCR2 receptor antagonists
WO2009032668A2 (en) 2007-08-28 2009-03-12 Irm Llc 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors
PE20091236A1 (en) 2007-11-22 2009-09-16 Astrazeneca Ab PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
PE20100087A1 (en) 2008-06-25 2010-02-08 Irm Llc COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
EP2326627A1 (en) * 2008-08-20 2011-06-01 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020245A (en) 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734488A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282574B2 (en) 2008-08-20 2014-08-21 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
MX2011012337A (en) 2009-05-21 2011-12-08 Dainippon Sumitomo Pharma Co Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases.
GB0908772D0 (en) 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
EA023350B1 (en) * 2009-10-16 2016-05-31 Мелинта Терапьютикс, Инк. Antimicrobial compounds, methods of making and using the same
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
EP2651937B8 (en) 2010-12-16 2016-07-13 Sumitomo Dainippon Pharma Co., Ltd. Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
WO2012113920A1 (en) 2011-02-24 2012-08-30 Katholieke Universiteit Leuven Arylsulfone derivatives with activity against human betaherpesviruses
JP6184423B2 (en) 2012-05-18 2017-08-23 大日本住友製薬株式会社 Carboxylic acid compound
CN106496190A (en) * 2016-10-18 2017-03-15 北京瑞济善健康科技有限公司 New type NS 5B inhibitor and application thereof
CN107951887A (en) * 2016-10-18 2018-04-24 李文超 A kind of antiviral drugs
CN107954983A (en) * 2016-10-18 2018-04-24 陈利华 Pyrimidinones and application thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308272A (en) * 1980-10-03 1981-12-29 The Upjohn Company Process for treating hypertension
GB2158068A (en) * 1984-04-26 1985-11-06 Aston Molecules Ltd Pyrimidine derivative solvate compounds
US5256668A (en) * 1993-03-17 1993-10-26 American Home Products Corporation Aminopyrimidine derivatives as antiviral agents for respiratory syncytial virus
WO1996010565A1 (en) * 1994-10-04 1996-04-11 Istituto Superiore Di Sanita' Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them
WO1996041634A2 (en) * 1995-06-13 1996-12-27 Sardinian Antiviral Research Consortium - Sarc S.C.R.L. Use of a non-nucleoside reverse transcriptase inhibitor in association with nucleoside inhibitors for the treatment of hiv infection
WO1997006804A1 (en) * 1995-08-19 1997-02-27 Glaxo Group Limited 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c
WO2000003998A1 (en) * 1998-07-17 2000-01-27 Novirio Pharmaceuticals Limited Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them
WO2000013708A1 (en) * 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308272A (en) * 1980-10-03 1981-12-29 The Upjohn Company Process for treating hypertension
GB2158068A (en) * 1984-04-26 1985-11-06 Aston Molecules Ltd Pyrimidine derivative solvate compounds
US5256668A (en) * 1993-03-17 1993-10-26 American Home Products Corporation Aminopyrimidine derivatives as antiviral agents for respiratory syncytial virus
WO1996010565A1 (en) * 1994-10-04 1996-04-11 Istituto Superiore Di Sanita' Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them
WO1996041634A2 (en) * 1995-06-13 1996-12-27 Sardinian Antiviral Research Consortium - Sarc S.C.R.L. Use of a non-nucleoside reverse transcriptase inhibitor in association with nucleoside inhibitors for the treatment of hiv infection
WO1997006804A1 (en) * 1995-08-19 1997-02-27 Glaxo Group Limited 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c
WO2000003998A1 (en) * 1998-07-17 2000-01-27 Novirio Pharmaceuticals Limited Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them
WO2000013708A1 (en) * 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANTONELLO MAI ET AL: "5-ALKYL-2-ALKYLTHIO-6-(2,6-DIHALOPHENYLMETHYL)-3,4-DIHYDROPYRIMIDIN-4 (3H)-ONES", JOURNAL OF MEDICINAL CHEMISTRY,AMERICAN CHEMICAL SOCIETY. WASHINGTON,US, vol. 42, 25 February 1999 (1999-02-25), pages 619 - 627, XP002123507, ISSN: 0022-2623 *
DALE A. STRINGFELLOW ET AL: "5-HALO-6- PHENYL PYRIMIDINES: A NEW SERIES OF INTERFERON- INDUCING AGENTS", INTERFERON: PROP. CLIN. USES, 1980, pages 315 - 326, XP000979815 *
LI, L. H. ET AL: "Effect of mouse hepatitis virus infection on combination therapy of P388 leukemia with cyclophosphamide and pyrimidinones", LAB. ANIM. SCI. (1987), 37(1), 41-4, XP002159448 *
MAI A ET AL: "SYNTHESIS AND ANTI-HIV-1 ACTIVITY OF THIO ANALOGUES OF DIHYDROALKOXYBENZYLOXOPYRIMIDINES", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 38, no. 17, 1995, pages 3258 - 3263, XP000578131, ISSN: 0022-2623 *
RENIS, H. E. ET AL: "Protection of mice from herpes simplex virus infection by 5-halo-6-aryl-isocytosines", CURR. CHEMOTHER. INFECT. DIS., PROC. INT. CONGR. CHEMOTHER., 11TH (1980), MEETING DATE 1979, VOLUME 2, 1411-13. EDITOR(S): NELSON, JOHN D.;GRASSI, CARLO. PUBLISHER: AM. SOC. MICROBIOL., WASHINGTON, D. C., XP000981311 *
WEED S D ET AL: "ANTI VIRAL PROPERTIES OF 6 ARYL PYRIMIDINES", CURR. CHEMOTHER. INFECT. DIS., 1980, pages P1408 - 1409, XP000981310 *

Also Published As

Publication number Publication date
AU6111000A (en) 2001-02-13
WO2001007027A2 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
WO2001007027A3 (en) Pyrimidine derivatives for the treatment of viral diseases
WO2002060926A3 (en) Hepatitis c tripeptide inhibitors
WO2004043339A3 (en) Substituted cycloalkyl p1' hepatitis c virus inhibitors
WO2004032827A3 (en) Hepatitis c virus inhibitors
TW200602350A (en) Methods and compositions for treating hepatitis C virus
RS100504A (en) Hepatitis c virus inhibitors
ATE539744T1 (en) INHIBITORS OF SERINE PROTEASE, IN PARTICULAR HEPATITIS C VIRUS NS3-NS4A PROTEASE, WITH A CONDENSED RING SYSTEM
WO2001079246A3 (en) 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
AP1771A (en) 3'-Prodrugs of 2'-deoxy-?-L-nucleosides.
IL152022A0 (en) Compounds useful as protease inhibitors and pharmaceutical compositions containing the same
MXPA04000293A (en) Bridged bicyclic serine protease inhibitors.
WO2005054430A3 (en) Hepatitis c virus inhibitors
AU2003248535A1 (en) Heterocyclicsulfonamide hepatitis c virus inhibitors
WO2002018369A3 (en) Peptidomimetic protease inhibitors
WO2002048116A3 (en) Inhibitors of hepatitis c virus ns3 protease
WO2002048157A3 (en) Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
WO2003053349A3 (en) Inhibitors of hepatitis c virus
ZA200109995B (en) Nematicidal Trifluorobutenes.
WO2002055025A3 (en) Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection
WO2002060954A8 (en) Materials and methods for treatment of hepatitis c
WO2003080631A8 (en) Plasma carboxypeptidase b inhibitors
MXPA03010737A (en) Aryl-8-azabicyclo[3.2.1]octanes for the treatment of depression.
EP1837024A3 (en) Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP